ostmenopausal bleeding is a serious and not uncommon clinical gynecologic occurrence that mandates evaluation. In fact, classic teaching has labeled postmenopausal bleeding as "endometrial cancer until proven otherwise." Studies indicate that the incidence of malignancy in such patients ranges from 1% to 14%, and obviously this rate will vary depending on the years since menopause and the classic risk of factors such as obesity, hypertension, diabetes, and low parity. 1
it will allow the patient to go directly to definitive therapy. However, when negative, it is not nearly as reliable as many clinicians have been led to believe. Blind sampling began with in-hospital dilation and curettage and was then replaced by the in-office Vabra aspirator (Berkley Medical Devices, Berkley, CA) and finally the current standard: the suction piston biopsy instrument. This device was first described in 1984 by Cornier 9 and was known as the Pipelle de Cornier. It is a plastic disposable catheter with its own internal piston to generate suction. It was designed to date the endometrium as part of an infertility workup, something no longer used in clinical practice. It was initially studied in 40 patients 10 with known carcinoma and in that widely publicized study achieved accuracy of 97.5% (39 of 40 patients). At least 3 similar studies in patients with known carcinoma using this device were carried out. [11] [12] [13] The number of cancers missed were 8%, 16%, and 33%, respectively. However, Guido et al 12 opened the uteri, and of 65 patients with cancer, the 11 cases that were missed all occupied less than 50% of the surface area of the uterine cavity. In addition, of 11 cancers in polyps, Pipelle missed 5. Perhaps most importantly, in only 46% of the cancers (30 of 65) did the tumor occupy more than 50% of the uterine cavity, but in all of these, Pipelle was successful in detecting the malignancy. The important message here is that endometrial cancer is often focal and not global, so blind endometrial sampling is not nearly as reliable as many clinicians would like to believe.
In summary, in women with postmenopausal bleeding, a thin distinct endometrial echo on transvaginal sonography has an extremely high negative predictive value (>99%). Not all uteri lend themselves to a meaningful sonographic evaluation. When the echo is not adequately visualized or seen but not sufficiently thin (<4 mm), saline infusion sonohysterography is a subset of transvaginal sonography that will clarify endometrial findings and triage patients to (1) no disease, (2) focal abnormality, or (3) global abnormality. Blind suction piston biopsy, unless positive, cannot be relied on to sufficiently exclude disease. Thus, "ultrasound first" as the approach to women who present with postmenopausal bleeding is "sound judgment." 
